In her introduction, Sandra Lourenco explained that even though the EU’s paediatric legislation came into effect more than 15 years ago, much medical need persists in the paediatric population. Global development of paediatric medicines can be facilitated by strengthening the international collaboration and alignment of regulatory requirements for PIPs. Therefore, it is important to collectively continue our efforts to develop medicinal products suitable for use in paediatric patients.